Treatment Expedition With MRI Processing and Optimization for Muscle Invasive Bladder Cancer
Launched by UNIVERSITY OF ROME TOR VERGATA · Jul 15, 2025
Trial Information
Current as of July 25, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial, called TEMPO-MIBC, is studying a new way to diagnose and treat muscle-invasive bladder cancer, a type of bladder cancer that has grown into the muscle layer of the bladder wall. The goal is to see if using a special type of MRI scan (called multiparametric bladder MRI) can help doctors skip a traditional surgical biopsy step and start treatment faster. Normally, patients have a procedure called TURBt, where doctors remove part of the tumor to check how far the cancer has spread. In this study, some patients will have the MRI first, and if it clearly shows muscle invasion, they will move directly to treatment without the biopsy. The researchers want to find out if this faster approach can lead to better outcomes and less time waiting for treatment.
People who might be eligible for this trial are adults 65 to 74 years old who have bladder cancer suspected to have invaded the muscle, confirmed by initial examinations. Patients won’t be eligible if they have very limited life expectancy, recent chemotherapy or radiation, severe kidney problems, certain metal implants, or if they’re pregnant or breastfeeding. Participants will have regular blood tests to measure tumor DNA in their bloodstream, which can help track how well treatment is working. Overall, this study aims to make bladder cancer diagnosis and treatment quicker and possibly more effective, which could improve long-term health for patients.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Clinical suspicion of muscle invasive bladder cancer at cystoscopy and pre-cystoscopy imaging
- Exclusion Criteria:
- • Anticipated survival \< 3 months due to comorbidities
- • Pregnant patients
- • Breastfeeding patients
- • Previous chemotherapy within 6 weeks
- • Previous radiotherapy withing 6 weeks
- • Previous TURBt within 6 weeks
- • Severe renal impairment (eGFR \< 40 mL/min/1.73 m2)
- • non MRI-compatible metal implants
- • Claustrophobia
- • Denial of written consent to participate in the study
About University Of Rome Tor Vergata
The University of Rome Tor Vergata is a prestigious academic institution recognized for its commitment to advancing medical research and education. As a clinical trial sponsor, it leverages its extensive resources and expertise in various fields of health sciences to foster innovative research initiatives. The university collaborates with healthcare professionals, researchers, and industry partners to conduct rigorous clinical trials aimed at improving patient care and outcomes. With a focus on ethical standards and scientific integrity, the University of Rome Tor Vergata is dedicated to contributing to the global body of medical knowledge and translating research findings into practical applications for the benefit of society.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Rome, Rm, Italy
Patients applied
Trial Officials
Simone Albisinni, MD, Phd, FEBU
Principal Investigator
Fondazione PTV Policlinico Tor Vergata
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported